Free Trial

Perrigo (PRGO) Stock Price, News & Analysis

Perrigo logo
$25.55 -0.86 (-3.26%)
(As of 03:28 PM ET)

About Perrigo Stock (NYSE:PRGO)

Key Stats

Today's Range
$25.50
$26.71
50-Day Range
$24.18
$28.91
52-Week Range
$23.89
$34.60
Volume
759,573 shs
Average Volume
1.60 million shs
Market Capitalization
$3.49 billion
P/E Ratio
N/A
Dividend Yield
4.31%
Price Target
$37.00
Consensus Rating
Moderate Buy

Company Overview

Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers. It also offers healthy lifestyle products, such as smoking cessation, well-being, and weight management products; skin care products consisting of dermatological care, scar management, lice treatment, and other products for various skin conditions; women's health products comprising feminine hygiene and contraceptives; vitamins, minerals, and supplements; rare diseases business; and other miscellaneous self-care products. The company sells its products under the Compeed, Dr. Fresh, Firefly, Good Sense, Good Start, Mederma, Nasonex, Plackers, Prevacid24HR, REACH, Rembrandt, Steripod, Opill, Solpadeine, Coldrex, Physiomer, NiQuitin, ACO, ellaOne, Compeed Stops, XLS, Arterin, Davitamon, Apiserum, Abtei, and Nicorette brands. It also offers contract manufacturing services. The company sells its products through retail drug, supermarket, and mass merchandise chains; e-commerce stores; wholesalers; pharmacies; drug and grocery retailers; and para-pharmacies. The company was formerly known as Perrigo Company and changed its name to Perrigo Company plc in December 2013. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.

Perrigo Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
100th Percentile Overall Score

PRGO MarketRank™: 

Perrigo scored higher than 100% of companies evaluated by MarketBeat, and ranked 9th out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Perrigo has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Perrigo has only been the subject of 2 research reports in the past 90 days.

  • Read more about Perrigo's stock forecast and price target.
  • Earnings Growth

    Earnings for Perrigo are expected to grow by 19.92% in the coming year, from $2.56 to $3.07 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Perrigo is -21.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Perrigo is -21.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Perrigo has a P/B Ratio of 0.73. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    2.95% of the outstanding shares of Perrigo have been sold short.
  • Short Interest Ratio / Days to Cover

    Perrigo has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Perrigo has recently decreased by 19.11%, indicating that investor sentiment is improving significantly.
  • Dividend Leadership

    Perrigo is a leading dividend payer. It pays a dividend yield of 4.00%, putting its dividend yield in the top 25% of dividend-paying stocks.

  • Dividend Growth

    Perrigo has been increasing its dividend for 22 years.

  • Dividend Sustainability

    Based on earnings estimates, Perrigo will have a dividend payout ratio of 35.83% next year. This indicates that Perrigo will be able to sustain or increase its dividend.

  • Read more about Perrigo's dividend.
  • Percentage of Shares Shorted

    2.95% of the outstanding shares of Perrigo have been sold short.
  • Short Interest Ratio / Days to Cover

    Perrigo has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Perrigo has recently decreased by 19.11%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Perrigo has a news sentiment score of 0.99. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 4 news articles for Perrigo this week, compared to 6 articles on an average week.
  • Search Interest

    7 people have searched for PRGO on MarketBeat in the last 30 days. This is an increase of 75% compared to the previous 30 days.
  • MarketBeat Follows

    Only 1 people have added Perrigo to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Perrigo insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $497,495.00 in company stock.

  • Percentage Held by Insiders

    Only 0.70% of the stock of Perrigo is held by insiders.

  • Percentage Held by Institutions

    95.91% of the stock of Perrigo is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Perrigo's insider trading history.
Receive PRGO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Perrigo and its competitors with MarketBeat's FREE daily newsletter.

PRGO Stock News Headlines

"X-Ray Vision" could find thousands of hidden market opportunities
Let me show you how I trade with “X-Ray vision.” You see, most “trend” traders only use one trend filter when looking for an optimal buy signal. And that can be a big mistake because you can’t see if you’re in a “True Trend.” But my newest trading tool is designed to only target the best, most stable stocks… Using 3 trend filters… which are these green, yellow, and red lines.
PRGO Crosses Above Key Moving Average Level
See More Headlines

PRGO Stock Analysis - Frequently Asked Questions

Perrigo's stock was trading at $32.18 at the beginning of the year. Since then, PRGO stock has decreased by 20.6% and is now trading at $25.55.
View the best growth stocks for 2024 here
.

Perrigo Company plc (NYSE:PRGO) posted its quarterly earnings data on Wednesday, November, 6th. The company reported $0.81 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $0.81. Perrigo's quarterly revenue was down 3.2% on a year-over-year basis.
Read the conference call transcript
.

Perrigo subsidiaries include these companies: HRA Pharma, Ranir, Laboratoire de la Mer SAS, Geiss Destin & Dunn, ScarAway, Omega Pharma, Elan Corporation, and others.

Top institutional investors of Perrigo include State Street Corp (4.77%), Thompson Siegel & Walmsley LLC (2.24%), Wellington Management Group LLP (1.98%) and Copeland Capital Management LLC (1.82%). Insiders that own company stock include Svend Andersen, Geoffrey M Parker, James E Dillard III, Robert Willis, Ronald Craig Janish, Patrick Lockwood-Taylor, Alison Ives, Grainne Quinn, Eduardo Guarita Bezerra, Katherine C Doyle, Jeffrey B Kindler, Thomas Farrington and Murray S Kessler.
View institutional ownership trends
.

Shares of PRGO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Perrigo investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Adobe (ADBE), Advanced Micro Devices (AMD), ServiceNow (NOW) and Arista Networks (ANET).

Company Calendar

Last Earnings
11/06/2024
Ex-Dividend for 12/17 Dividend
11/29/2024
Dividend Payable
12/17/2024
Today
12/18/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
CUSIP
71429010
Employees
9,140
Year Founded
1887

Price Target and Rating

Average Stock Price Target
$37.00
High Stock Price Target
$42.00
Low Stock Price Target
$30.00
Potential Upside/Downside
+41.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
4 Analysts

Profitability

Net Income
$-12,700,000.00
Pretax Margin
-4.67%

Debt

Sales & Book Value

Annual Sales
$4.39 billion
Cash Flow
$5.03 per share
Book Value
$35.19 per share

Miscellaneous

Free Float
135,473,000
Market Cap
$3.58 billion
Optionable
Optionable
Beta
0.52

Social Links

Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

This page (NYSE:PRGO) was last updated on 12/18/2024 by MarketBeat.com Staff
From Our Partners